drugset / Trial / NCT01946568
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
NaSingle-groupOpen-label
Summary
A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
Timeline
- Start
- 2013-06
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalbavancin | Other / unclassified | 15 mg/kg | Intravenous |
| Subject | Dalbavancin | Other / unclassified | 25 mg/kg | Intravenous |